A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Pre-menopausal Breast Cancer|PI3K Pathway Inhibition
Interventions: DRUG: alpelisib (BYL719)|DRUG: buparlisib (BKM120)
Sponsor: Novartis Pharmaceuticals